ponvory

Generic: ponesimod

ponvory: developed by 1 company · 1 FDA decision. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
Vanda Pharmaceuticals Inc. (VNDA)Approved

FDA Decisions

Approval1 INDICATIONS AND USAGE PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PONVORY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )(VNDA)

Frequently asked questions

Who is developing ponvory?

ponvory is being developed by Vanda Pharmaceuticals Inc..

What is ponvory's latest FDA decision?

The most recent tracked FDA decision for ponvory is Approval for 1 INDICATIONS AND USAGE PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PONVORY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 ), dated March 18, 2021.

Get deeper analysis on ponvory

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    ponvory — Drug Pipeline, Trials & FDA Status | BioSniper